Akash Tewari
Stock Analyst at Jefferies
(1.54)
# 3,269
Out of 4,876 analysts
59
Total ratings
32.56%
Success rate
-3.37%
Average return
Main Sectors:
Stocks Rated by Akash Tewari
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARVN Arvinas | Downgrades: Hold | $52 → $10 | $7.80 | +28.21% | 3 | May 2, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $70 → $68 | $46.65 | +45.77% | 4 | Apr 23, 2025 | |
| BMRN BioMarin Pharmaceutical | Initiates: Outperform | $95 | $54.10 | +75.60% | 2 | Nov 15, 2024 | |
| BNTX BioNTech SE | Upgrades: Buy | $96 → $150 | $106.14 | +41.32% | 3 | Sep 17, 2024 | |
| RLAY Relay Therapeutics | Upgrades: Buy | $11 → $16 | $3.32 | +381.93% | 3 | Sep 10, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $177 → $189 | $126.71 | +49.16% | 2 | Aug 19, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $80 | $18.40 | +334.78% | 2 | Jul 31, 2024 | |
| IONS Ionis Pharmaceuticals | Upgrades: Buy | $29 → $75 | $39.78 | +88.54% | 1 | Jul 16, 2024 | |
| LLY Eli Lilly and Company | Maintains: Buy | $994 → $1,015 | $795.12 | +27.65% | 6 | Jun 24, 2024 | |
| ALKS Alkermes | Maintains: Buy | $42 → $50 | $28.83 | +73.43% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $37 → $75 | $43.81 | +71.19% | 4 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $16.03 | +93.39% | 1 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $935 → $937 | $521.00 | +79.85% | 4 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $38 → $39 | $24.24 | +60.89% | 2 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $49 → $18 | $7.51 | +139.68% | 2 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $497 → $513 | $560.04 | -8.40% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.00 | +350.00% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $78.83 | +58.57% | 1 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7.7 → $11 | $12.37 | -11.08% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $30 → $3.6 | $5.45 | -33.88% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $1.31 | +1,197.71% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $33.91 | +121.17% | 2 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $151 | $299.51 | -49.58% | 1 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $43.09 | -35.02% | 3 | Oct 7, 2021 |
Arvinas
May 2, 2025
Downgrades: Hold
Price Target: $52 → $10
Current: $7.80
Upside: +28.21%
Bristol-Myers Squibb Company
Apr 23, 2025
Maintains: Buy
Price Target: $70 → $68
Current: $46.65
Upside: +45.77%
BioMarin Pharmaceutical
Nov 15, 2024
Initiates: Outperform
Price Target: $95
Current: $54.10
Upside: +75.60%
BioNTech SE
Sep 17, 2024
Upgrades: Buy
Price Target: $96 → $150
Current: $106.14
Upside: +41.32%
Relay Therapeutics
Sep 10, 2024
Upgrades: Buy
Price Target: $11 → $16
Current: $3.32
Upside: +381.93%
Neurocrine Biosciences
Aug 19, 2024
Maintains: Buy
Price Target: $177 → $189
Current: $126.71
Upside: +49.16%
Apellis Pharmaceuticals
Jul 31, 2024
Maintains: Buy
Price Target: $80
Current: $18.40
Upside: +334.78%
Ionis Pharmaceuticals
Jul 16, 2024
Upgrades: Buy
Price Target: $29 → $75
Current: $39.78
Upside: +88.54%
Eli Lilly and Company
Jun 24, 2024
Maintains: Buy
Price Target: $994 → $1,015
Current: $795.12
Upside: +27.65%
Alkermes
Apr 9, 2024
Maintains: Buy
Price Target: $42 → $50
Current: $28.83
Upside: +73.43%
Mar 6, 2024
Maintains: Buy
Price Target: $37 → $75
Current: $43.81
Upside: +71.19%
Dec 11, 2023
Initiates: Buy
Price Target: $31
Current: $16.03
Upside: +93.39%
Nov 28, 2023
Maintains: Buy
Price Target: $935 → $937
Current: $521.00
Upside: +79.85%
Oct 16, 2023
Upgrades: Buy
Price Target: $38 → $39
Current: $24.24
Upside: +60.89%
Aug 8, 2023
Downgrades: Hold
Price Target: $49 → $18
Current: $7.51
Upside: +139.68%
Jul 17, 2023
Maintains: Buy
Price Target: $497 → $513
Current: $560.04
Upside: -8.40%
Jun 7, 2023
Initiates: Buy
Price Target: $18
Current: $4.00
Upside: +350.00%
Mar 6, 2023
Initiates: Buy
Price Target: $125
Current: $78.83
Upside: +58.57%
Dec 20, 2022
Upgrades: Buy
Price Target: $7.7 → $11
Current: $12.37
Upside: -11.08%
Dec 16, 2022
Downgrades: Hold
Price Target: $30 → $3.6
Current: $5.45
Upside: -33.88%
Dec 12, 2022
Initiates: Buy
Price Target: $17
Current: $1.31
Upside: +1,197.71%
Oct 7, 2021
Initiates: Buy
Price Target: $75
Current: $33.91
Upside: +121.17%
Oct 7, 2021
Initiates: Buy
Price Target: $151
Current: $299.51
Upside: -49.58%
Oct 7, 2021
Initiates: Buy
Price Target: $28
Current: $43.09
Upside: -35.02%